Clinical trial
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00102635 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00102635 |
|---|---|
| Title | 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Official title | A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Schering-Plough Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Fenretinide (4-HPR), SCH66336 |
| Enrollment | 1 |
| Start date | Jan 20, 2005 |
| Primary completion | Jan 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Feb 1, 2005 |
| Last update posted | Nov 15, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: